SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is the main focus, with management saying the application is in final review and reaffirming confidence in the therapy. Traders are reading comments about possible labeling as encouraging, fueling bullish positioning and short-squeeze speculation, while others stress that approval remains uncertain and the decision is a binary risk.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras positive Phase 2 results for ABCL635, its investigational treatment for menopausal hot flashes, alongside upbeat management comments, analyst target increases and new pipeline programs, are driving attention. Many traders see substantial potential, while others are frustrated by the stocks weak reaction and emphasize that durability data and progress toward Phase 3 remain key tests.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUM is drawing attention after reporting record quarterly revenue and its first positive adjusted EBITDA, with traders focused on Quake AIs contribution and the companys shift toward AI infrastructure. Many are bullish and anticipating a short squeeze, while others question cash needs, financing and data-center expansion timelines.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA for sonelokimab in hidradenitis suppurativa and the pending FDA filing-review decision dominate discussion, alongside the drugs clinical prospects. Traders are divided between optimism about the pipeline and a potential buyout, and concerns about regulatory risk, competition, and the cost of commercializing the drug independently.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A broad semiconductor rebound tied to CoreWeaves strong results and renewed confidence in AI-infrastructure demand has lifted AMD. Traders are cheering AMDs strength and some see money rotating from Nvidia, while others warn the rapid rally may be overextended and expect profit-taking.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Repeated extensions in Aurinias generic-drug patent litigation are keeping attention on the timing and outcome of the cases, with traders frustrated by the delays and the companys limited communication. Some speculate that the cases could settle or lead to a buyout, but neither outcome is confirmed; others point to the recent revenue-guidance increase as a positive counterweight.

BankrCoin (BNKR) is a cryptocurrency and operates on the Base platform. BankrCoin has a current supply of 100,000,000,000 with 99,389,999,999.99966667 in circulation. The last known price of BankrCoin is 0.00025632 USD and is up 4.30 over the last 24 hours. It is currently trading on 84 active market(s) with $1,502,887.40 traded over the last 24 hours. More information can be found at https://warpcast.com/bankr.

BankrCoin

BNKRs volatile price moves and repeated breakout speculation are drawing attention, with bullish traders pointing to Bankrs expanding AI-agent trading integrations, protocol activity, staking and fee-linked buybacks. Others warn that rallies may fade and question whether usage and revenue translate into lasting token value.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUEs strong initial commercial launch and better-than-expected product revenue are driving attention, but RVMD shares have sold off sharply despite the upbeat results. Traders are debating whether the decline reflects profit-taking and concerns about launch durability and rising expenses or an overreaction to the companys early commercial momentum.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

Cardinals steep selloff is being attributed mainly to concerns over its Hughes Brothers acquisition, with traders questioning the deals cost, potential dilution, and managements handling of margins and capital allocation. Some also point to securities-law investigations and loss of investor confidence, while bullish traders argue the shares are oversold and undervalued.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is drawing attention ahead of its upcoming earnings report, with traders focused on whether AI-driven chipmaking investment and equipment orders support the outlook. The recent rally and call-heavy options activity have encouraged bullish positioning, while others warn that fab spending could weaken and make the shares vulnerable to a pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXPR NewswireNEW YORK, Nov. 5, 2026 NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating...

Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX

Investors should consider buying resurgent healthcare and biotech stocks amid the AI selloff. Today, we are digging into why it might be time to buy biopharmaceutical stock Argenx (ARGX).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is...

HRMY or ARGX: Which Is the Better Value Stock Right Now?

HRMY vs. ARGX: Which Stock Is the Better Value Option?

argenx Q3 2026 Earnings Call Transcript

argenx (NASDAQ:ARGX) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

Argenx Earnings Up In Q3

(RTTNews) - argenx SE (ARGX), an immunology innovation company, on Thursday reported higher net income in the third quarter compared with the previous year...

Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR

Cummins, Argenx and PACCAR offer potential buying opportunities after recent pullbacks, backed by strong earnings growth, improving forecasts and long-term business drivers.

Best 3 Non-AI Stocks to Buy Now on the Dip Amid the AI Stock Selloff

Diving into three great stocks to buy at a discount and hold that are posting impressive earnings and revenue growth outside of the AI boom.

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

Argen X SE - ADR

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>IMVT-1402 missed its main goal in a cutaneous lupus study in September, and that program was dropped.</li><li>H.C. Wainwright termed Argenx’s trial halt in Sjögren’s a “surprising setback.”</li><li>Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage study.</li></ul><p>Shares of Immunovant (IMVT) sold off Thursday as traders treated Argenx’s (ARGX) failed late-stage Sjögren’s trial as a warning for its own experimental drug for the autoimmune disorder.</p><p>Immunovant (IMVT) fell about 6% to $30.06 in morning trading. Its parent Roivant (ROIV) was also weaker, trading down roughly 2%.</p><h2 class="st-heading-2">Why Did IMVT, ROIV Fall On Rival Trial?</h2><p>Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease. Argenx’s efgartigimod works the same way: it lowers circulating IgG antibodies that can drive autoimmune disease.</p><p>A late-stage failure for a closely related drug raises the odds that simply reducing IgG may not be enough in Sjögren’s. The move also follows Immunovant’s late-September setback, when IMVT-1402 missed its main goal in a cutaneous lupus study, and that program was dropped.</p><p>Roivant is the majority owner of Immunovant, and IMVT-1402 is central to the group’s autoimmune story.</p><h2 class="st-heading-2">ARGX’s Failed Trial</h2><p>Argenx has stopped its late-stage UNITY study of weekly subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease. An independent monitoring committee, after an interim look, said the trial was unlikely to meet its main goal: a reduction in systemic disease activity at week 48, the company said. Safety matched the drug’s known profile, with no new signals.</p><p>Sjögren’s, which causes dry eyes, dry mouth, fatigue and joint pain, still has no approved targeted therapy and is unusually varied from patient to patient, which makes trials hard to win.</p><p>Argenx’s U.S. shares were down about 14% to $797.69. The drug is already approved as Vyvgart for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The failed trial removes the Sjögren’s path for Vyvgart.</p><h2 class="st-heading-2">Analyst Weighs In On ARGX’s Failed Trial</h2><p>H.C. Wainwright analyst Douglas Tsao called it a good-news, bad-news day for Argenx. On the positive side, the analyst said a 126-patient mid-stage study of FB102 in celiac disease met its primary endpoint. Argenx acquired FB102 through its $2.2 billion acquisition of Forte Biosciences. The firm sees that result as real validation of Argenx’s Forte deal and a clear step toward a late-stage study.</p><p>The UNITY stop, by contrast, was a “surprising setback,” the firm said. Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage Sjögren’s study of IMVT-1402. It kept a ‘Buy’ on Argenx and a $1,202 price target.</p><h2 class="st-heading-2">How Did IMVT, ROIV, ARGX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around IMVT and ROIV was in 'neutral' and 'bearish' territory, respectively.</p><p>Sentiment around ARGX, however, jumped from 'bearish' to 'bullish' territory.</p><p><a class="mention" data-mention="$IMVT" data-symbol-id="IMVT" href="https://stocktwits.com/symbol/IMVT" target="_blank">IMVT stock</a> has gained 19% this year, while ROIV has gained 55%. ARGX, however, has lost 4%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-reportedly-bought-up-to-25-m-in-meta-stock-the-largest-reported-purchase-among-517-transactions/cZDUoxfRBNw">Trump Reportedly Bought Up To $25M In Meta Stock, The Largest Reported Purchase Among 517 Transactions</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Argenx

Immunovant Inc

Roivant Sciences Ltd

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$8.08	--	--	N/A
Q3 '26	$7.98	$7.80	-2.29%	MISSED
Q2 '26	$6.54	$7.32	11.90%	BEAT
Q1 '26	$5.38	$5.52	2.65%	BEAT
Q4 '25	$5.93	$8.02	35.27%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARGX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings